Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents

Definitions

• This invention relates to a novel 5-fluorouracil derivative having the general formula (I) ##STR2## wherein R 1 , R 2 and R 3 each represent hydrogen atom or methyl group, and R 4 represents a straight or branched alkyl or alkenyl group.
• R 1 , R 2 and R 3 each represent hydrogen atom or methyl group
• R 4 represents a straight or branched alkyl or alkenyl group.
• This invention also relates to antitumor preparations containing said novel derivative.
• alkylating agents such as busulfan, chlorambutyl, merphalan and the like
• antimetabolics such as methotrexate, 6-mercaptopurine, 6-mercaptopurine ribo-nucleoside, 5-fluorouracil, and the like, for chemotherapeutics to various malignant tumors such as gastric cancer, hepatoma, bladder cancer, seminoma, leukemia, lymphosarcoma, breast cancer, lung cancer, uterine cancer and the like.
• 5-fluorouracil has clinical utility.
• FT-207 shows remarkably lower toxicity, i.e., 1/7-1/5 of that of 5-fluorouracil per se and less antitumor activity.
• a considerably long period of time is required to obtain remission by administration of FT-207 alone.
• novel 5-fluorouracil derivatives which show less toxicity than the known 5-fluorouracil, and also FT-207 and maintain high antitumor activity. And, we found that the desired object is attained by the derivatives (I) according to this invention.
• An object of this invention is therefore to provide novel 5-fluorouracil derivatives having the general formula (I) as described above.
• Another object of this invention is to provide a process for the preparation of 5-fluorouracil derivatives.
• a further object of this invention is to provide novel antitumor preparations containing the 5-fluorouracil derivatives.
• a still further object of this invention is to provide a method for treating various malignant tumors such as gastric cancer, hepatoma, bladder cancer, seminoma, leukemia, lymphosarcoma, breast cancer, lung cancer, uterine cancer, and the like.
• 5-fluorouracil is reacted with a carbonate of 6-chromanol derivative having the general formula (II): ##STR3## wherein R 1 , R 2 , R 3 and R 4 have the same meanings as defined above, and X represents a halogen atom or a lower alkoxyl group, to obtain the desired derivatives (I).
• the starting material, 5-fluorouracil in a form of an alkali metal salt thereof.
• the reaction can advantageously progress by using an organic solvent such as dimethyl formamide, dimethyl acetamide, and the like.
• the reaction proceeds in an equimolar state and preferably at a temperature ranging from room temperature to about 50° C.
• FT-207 and 5-fluorouracil are selected as standard drugs.
• Compound A was administered as a solution of soybean oil and 5-FU was administered as saline solution, at 24 hours after the implantation.
• Soybean oil was administered as control for the Compound A.
• Saline solution was administered as control for 5-FU.
• TPCV total packed cell volumes
• ED 50 of the Compound A of this invention is about 170 mg/Kg and its safety index (LD 50 /ED 50 ) is more than 24, while ED 50 of 5-FU is about 25 mg/Kg and its safety index is about 5. These results show that Compound A is less toxic as an antitumor agent.
• Compound A was administered as a solution of soybean oil at 24 hours after the implantation.
• Soybean oil was administered as control for Compound A.
• Each of the drugs was orally administered as a solution of safflower oil 3 hours after the implantation.
• Safflower oil was administered as control for each of the drugs.
• the minimum effective dose of Compound A is about 250 mg/Kg, that of FT-207 is about 100 mg/Kg, and that of 5-FU is about 20 mg/Kg.
• the ratios of the minimum effective dose to toxic dose (LD 50 ) in each of the drugs Compound A gives less than 1/16; FT-207 gives about 1/10; and 5-FU gives about 1/6. Therefore, the availability of the Compound A is higher than those of the other two drugs.
• Compound A was intraperitoneally administered as a solution of medium chain triglyceride (MCT) at 24 hours after the implantation.
• MCT medium chain triglyceride
• Each of 5-FU and FT-207 was also intraperitoneally administered as a saline solution at 24 hours after the implantation.
• MCT was administered as control for Compound A.
• Saline solution was administered as controls for 5-FU and FT-207.
• the ratio of said dose to the LD 50 in the Compound A is smaller than that of 5-FU. Therefore, the availability of the Compound A is higher than that of 5-FU.
• Compound A was intraperitoneally administered in CDF 1 mice (female, 8-10 weeks old) as a solution of MCT, before the implantation as shown in Table 6.
• FT-207 and 5-FU were intraperitoneally administered as a saline solution, before the implantation as shown in Table 6.
• MCT was administered as control for Compound A.
• Saline solution was administered as controls for FT-207 and 5-FU.
• the derivatives of this invention have very lower toxicity and a broader range between toxic dose and effective dose than those of 5-FU and FT-207. Duration of the derivatives of this invention is more effective than with 5-FU and FT-207. In these points, the derivatives of this invention are excellent antitumor agents.
• Dose of the derivatives of this invention as antitumor agents amount to about 1-200 mg/Kg per day, preferably 5-100 mg/Kg for adult.
• the derivatives of this invention may be administered either orally or parenterally.
• administration form powder, granule, tablet, capsule, liquid for injection, suppository and ointment can be available.
• formulations can be prepared by using a conventional excipient by means of a conventional process.
• a suspension was prepared by adding 10.3 g (0.13 mols) of 55% oily sodium hydride to 100 ml of dimethyl formamide. The suspension was cooled to below 5° C. 150 ml of dimethyl formamide solution containing 16.9 g (0.13 mols) of 5-fluorouracil were added slowly dropwise to the suspension while stirring for 30 minutes, and the mixed solution was further kept for one hour at the same condition. To the solution, 100 ml of dimethyl formamide solution containing 64.1 g (0.13 mols) of d,l- ⁇ -tocopheryl chloroformate were added slowly dropwise for 30 minutes. The solution was heated to 40° C. and stirred for additional one hour.
• the reaction solution was allowed to cool to a room temperature, and subjected to the filtration.
• the filtrate was concentrated under a reduced pressure.
• the resulting residue in the amount of 76 g was extracted twice with 300 ml of benzene, respectively.
• the benzene extract was concentrated under a reduced pressure.
• the resulting residue in the amount of 71 g was recrystallized from ethanol to obtain the object material in a white crystalline powder having a melting point of 119°-120° C.
• N 1 -d,l- ⁇ -tocopheryl carbonyl-5-fluorouracil, micro-crystallized cellulose, corn starch and lactose were mixed altogether.
• Aqueous polyvinyl pyrolidone solution was added as a binder to this mixture, and the whole was granulated by a conventional process. These granules were filled in hard gelatinous capsules, to form the capsules.
• N 1 -d,l- ⁇ -tocopheryl carbonyl-5-fluorouracil, micro-crystallized cellulose, corn starch, lactose and calcium carboxymethyl cellulose were mixed altogether.
• Aqueous polyvinyl pyrolidone solution was added as a binder to said mixture, and the whole was granulated by a conventional process.
• the granules were admixed with the talc, to form tablets of 200 mg per tablet.
• a liquid for injection was prepared by a conventional method.
• N 1 -d,l- ⁇ -tocopheryl carbonyl-5-fluorouracil Forty grams of N 1 -d,l- ⁇ -tocopheryl carbonyl-5-fluorouracil were dissolved in one liter of O. D. O. (medium chain triglyceride produced and sold by Nisshin Oil Co., Ltd., Japan). This solution was put in a film of soft capsule of gelatine to obtain a suppository.
• O. D. O. medium chain triglyceride produced and sold by Nisshin Oil Co., Ltd., Japan

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=15595270

Family Applications (1)

Country Status (14)

Cited By (5)

Families Citing this family (1)

Citations (1)

• 1976
  • 1976-12-24 JP JP51154941A patent/JPS6052708B2/ja not_active Expired
• 1977
  • 1977-12-14 US US05/860,319 patent/US4130648A/en not_active Expired - Lifetime
  • 1977-12-20 FR FR7738495A patent/FR2378779A1/fr active Granted
  • 1977-12-21 CH CH1581377A patent/CH636874A5/de not_active IP Right Cessation
  • 1977-12-21 NL NL7714205A patent/NL7714205A/xx not_active Application Discontinuation
  • 1977-12-21 AU AU31825/77A patent/AU519524B2/en not_active Expired
  • 1977-12-22 GB GB53541/77A patent/GB1594840A/en not_active Expired
  • 1977-12-22 BE BE183769A patent/BE862213A/fr not_active IP Right Cessation
  • 1977-12-22 DE DE19772757431 patent/DE2757431A1/de not_active Withdrawn
  • 1977-12-22 SE SE7714670A patent/SE436208B/sv not_active IP Right Cessation
  • 1977-12-23 CA CA293,822A patent/CA1077483A/fr not_active Expired
  • 1977-12-23 SU SU772559705A patent/SU827489A1/ru active
  • 1977-12-23 PH PH20592A patent/PH12700A/en unknown
  • 1977-12-23 ES ES465406A patent/ES465406A1/es not_active Expired
• 1979
  • 1979-06-18 SU SU792778129A patent/SU795469A3/ru active

Patent Citations (1)

Also Published As

Similar Documents